Strategic partnerships Leverage SpiroChem’s strong collaboration history with CROs and pharma players (EUROAPI UK, Arctoris, Dalriada Drug Discovery, BaseLaunch) to propose joint offerings, co-developed projects, and extended service scopes to prospective customers seeking integrated chemistry and biology support.

North American access Capitalize on the 2023 acquisition of Cyclenium Pharma to emphasize macrocyclic therapeutic capabilities and North American market reach, offering clients macrocyclic and specialized chemistry expertise alongside established Basel operations.

Full-scope chemistry Position as a one-stop partner from hit validation through lead optimization to early process R&D, targeting biotech firms needing end-to-end discovery and process chemistry solutions to accelerate regulatory milestones.

Regulatory readiness Highlight advisory, reporting, and regulatory milestone support as a differentiator for customers aiming to de-risk projects and streamline IND/clinical development, especially for complex chemistry challenges.

High engagement Emphasize exceptional communication, transparency, and team-embedded collaboration to appeal to mid-market biotech startups and scale-ups seeking reliable, hands-on CRO partnerships with rapid responsiveness.